# Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy

Study · id `cardio:ct-nct04667143` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04667143](<https://clinicaltrials.gov/study/NCT04667143>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04667143

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 760 participants.

## Technical summary

Registry record NCT04667143. Randomized; quadruple masking; primary purpose treatment. Start 2021-01 (anticipated); primary completion 2022-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 760 participants (planned count; ClinicalTrials.gov record NCT04667143, source copy `cardio:ctgov-nct04667143-2020-12-14`, retrieved 2026-10-26)
- Planned start: 2021-01 (anticipated) (ClinicalTrials.gov record NCT04667143, source copy `cardio:ctgov-nct04667143-2020-12-14`, retrieved 2026-10-26)
- Primary completion: 2022-09 (anticipated) (ClinicalTrials.gov record NCT04667143, source copy `cardio:ctgov-nct04667143-2020-12-14`, retrieved 2026-10-26)
- Completion: 2022-10 (anticipated) (ClinicalTrials.gov record NCT04667143, source copy `cardio:ctgov-nct04667143-2020-12-14`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04667143-2020-12-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy
- Condition: Diabetes Mellitus, Type II
- Intervention (Drug): Retagliptin, Henagliflozein, metformin XR
- Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Jiangsu HengRui Medicine Co., Ltd. (`cardio:org-jiangsu-hengrui-medicine-co-ltd`)

## Provenance

Content hash: f2ed0ff42f8a1d9ad368a4da10eee5214ff71b4f14faeff6ef222887c95b490e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
